The goal of this clinical research trial is to study the effects of the FDA-approved drug,
temsirolimus, using a new type of clinical study design called a "Phase 0." This type of
study may be able to predict if a drug can affect cancer and may be able to prevent
potentially useful study drugs from being discarded before they are fully tested.
The purpose of the study is not to treat the cancer, but to help improve general cancer
treatment knowledge.